Jounce Therapeutics

Jounce Therapeutics is developing novel cancer immunotherapies that target the ICOS (Inducible Costimulatory Receptor) protein. ICOS is a cell surface receptor that is expressed on activated T cells. When ICOS binds to its ligand, ICOSL, it sends a signal that can either activate or suppress the T cell, depending on the context. In cancer, ICOS signaling can help to suppress the immune system's ability to attack tumor cells. Jounce Therapeutics is developing ICOS antagonists, which are drugs that block the interaction between ICOS and ICOSL. By blocking ICOS signaling, Jounce Therapeutics hopes to activate the immune system and help the body fight cancer.

Jobs: